ArticleTranslational andrology and urology2026
Bioinformatics analysis and experimental approach identify BRD-family gene
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a highly prevalent malignant tumor within the urinary system, bladder cancer (BLCA) is manifested as frequent recurrence and substantial prognostic heterogeneity. The development of BLCA is strongly linked to epigenetic dysregulation. Bromodomain-containing proteins (BRDs)-related genes (BRDRGs) serve as critical regulators across various cancers. However, the expression profiles, prognostic significance, and influence on the tumor immune microenvironment (TIME) of BRDRGs in BLCA remain underexplored. This study aimed to systematically explore the expression and prognostic significance of BRD-related genes in BLCA and to construct a BRD-based prognostic model. Methods: Utilizing transcriptomic data within The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) for BLCA, BRDRGs were screened through GeneCards. Consensus clustering was leveraged to define BRD molecular subtypes. Differential expression analysis was implemented to ascertain BRD co-expressed genes, and we intersected them with differentially expressed genes (DEGs) between tumor and normal samples in TCGA-BLCA to obtain differentially expressed BRD genes (DE-BRDRGs). A prognostic risk model was developed utilizing univariate Cox and least absolute shrinkage and selection operator (LASSO) regression, followed by survival analysis, receiver operating characteristic (ROC) evaluation, and nomogram validation. Associations between the model and immune characteristics with immunotherapy response were estimated utilizing Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT), Tumor Immune Dysfunction and Exclusion (TIDE), and pRRophetic analyses. Gene set enrichment analysis (GSEA) was implemented to ascertain functions of key genes. Results: In total, 1,572 upregulated genes and 1,111 downregulated genes were ascertained from TCGA-BLCA, with 36 DE-BRDRGs ultimately ascertained through the intersection of BRD co-expressed genes. Seven genes ( Conclusions: This research ascertained seven key BRDRGs and comprehensively analyzed their functions in BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.